Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (31-40 of 232) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
Measuring Toxicity in Phase I Clinical Trials--LetterDavid M Hyman, Anne Eaton, S Percy Ivy, et al.
Cancer Investigation|March 21, 2002
Oxaliplatin: a review of evolving conceptsSridhar Mani, Martin A Graham, David B Bregman, et al.
Clinical Lung Cancer|July 6, 2011
Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trialsShirish M Gadgeel, Percy Ivy, Wei Chen, et al.
Frontiers in Oncology|April 20, 2017
Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor CancersCharles A Kunos, Edward Chu, Della Makower, et al.
Frontiers in Oncology|November 5, 2019
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal CancersCharles A Kunos, Stephen J Andrews, Kathleen N Moore, et al.
Expert Opinion on Investigational Drugs|February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerS Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.
Journal of the National Cancer Institute|November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Frontiers in Oncology|October 26, 2019
Clinical Outcome Assessments Toolbox for RadiopharmaceuticalsCharles A Kunos, Jacek Capala, Adam P Dicker, et al.
Investigational New Drugs|October 31, 2003
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancerMaha Hussain, Ulka Vaishampayan, Lance K Heilbrun, et al.
Pageof 24

Showing results (31-40 of 232) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
Measuring Toxicity in Phase I Clinical Trials--LetterDavid M Hyman, Anne Eaton, S Percy Ivy, et al.
Cancer Investigation|March 21, 2002
Oxaliplatin: a review of evolving conceptsSridhar Mani, Martin A Graham, David B Bregman, et al.
Clinical Lung Cancer|July 6, 2011
Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trialsShirish M Gadgeel, Percy Ivy, Wei Chen, et al.
Frontiers in Oncology|April 20, 2017
Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor CancersCharles A Kunos, Edward Chu, Della Makower, et al.
Frontiers in Oncology|November 5, 2019
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal CancersCharles A Kunos, Stephen J Andrews, Kathleen N Moore, et al.
Expert Opinion on Investigational Drugs|February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerS Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.
Journal of the National Cancer Institute|November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Frontiers in Oncology|October 26, 2019
Clinical Outcome Assessments Toolbox for RadiopharmaceuticalsCharles A Kunos, Jacek Capala, Adam P Dicker, et al.
Investigational New Drugs|October 31, 2003
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancerMaha Hussain, Ulka Vaishampayan, Lance K Heilbrun, et al.
Pageof 24